Use of pragmatic randomized trials in multiple sclerosis: A systematic overview
Source : https://pubmed.ncbi.nlm.nih.gov/38253528/
Only few and mostly small pragmatic trials exist in MS which rarely assess drugs. Despite the widely available routine data infrastructures, very few trials utilize them. There is an urgent...
Pragmatic trials in multiple sclerosis (MS) are limited, with few assessing drugs and seldom using routine data, highlighting the need for more real-world evidence studies.
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Source : https://pubmed.ncbi.nlm.nih.gov/38918831/
Multiple Sclerosis (MS) is a complex autoimmune disorder that significantly impacts the central nervous system, leading to a range of complications. While intracranial haemorrhage (ICH) is a rare but highly...
MS management is challenged by the risk of ICH, influenced by DMDs like Dimethyl Fumarate and Fingolimod, requiring personalized strategies considering patient-specific factors and ongoing research.
Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study
Source : https://pubmed.ncbi.nlm.nih.gov/38450623/
Multiple sclerosis (MS) is a chronic neuro-inflammatory disease resulting in disabilities that negatively impact patients' life quality. While current treatment options do not reverse the course of the disease, treatment...
A study demonstrated the safety and potential efficacy of two UC-MSC treatment protocols in MS patients, with better outcomes observed in the two-dose group.
Headache in Multiple Sclerosis: A Narrative Review
Source : https://pubmed.ncbi.nlm.nih.gov/38674218/
Background : Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system characterized by autoimmune-mediated damage to oligodendrocytes and subsequent myelin destruction. Clinical implications : Clinically,...
Headache, common in MS patients, often signals early disease and can be exacerbated by some therapies. Understanding this link aids in better patient management and treatment decisions.
Understanding multiple sclerosis as a disease spectrum: above and below the clinical threshold
Source : https://pubmed.ncbi.nlm.nih.gov/38535979/
Aligning on a consistently-applied mechanistic framework at distinct levels of explanation will enable greater precision across bench and clinical research, and inform discourse on drivers of disability progression and delivery...
Adopting a unified mechanistic framework for MS will enhance precision in research, prognostication, and treatment, bridging gaps between pathobiology and clinical outcomes.